Frankfurt - Delayed Quote EUR

HBM Holdings Limited (6XY.F)

0.9000

+0.0500

+(5.88%)

At close: April 25 at 8:41:26 PM GMT+2

Harbour BioMed Appoints Youchen Chen as Chief Financial Officer

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Youchen (YC) Chen as Chief Financial Officer. YC will be based in Shanghai and Hong Kong SAR, and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.

PR Newswire 17 days ago

HBMHF
Harbour BioMed Reports Full Year 2024 Financial Results

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its financial results for the year ended December 31, 2024.

PR Newswire 27 days ago

HBMHF
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced a global strategic collaboration with AstraZeneca to discover and develop next-generation multi-specific antibodies for immunology, oncology and beyond. The strategic collaboration includes an option to license multiple programs utilizing Harbour BioMed's proprietary Harbour Mice® fully human anti

PR Newswire last month

HBMHF
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced the launch of Élancé Therapeutics ("Élancé"). Harnessing Harbour BioMed's proprietary HCAb-based bispecific antibody technology, Élancé aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle preservation and long-term efficacy.

PR Newswire last month

HBMHF
Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Dr. Ian Y. Liu as Senior Vice President, Global Head of Legal. Dr. Liu will be based in the U.S. and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.

PR Newswire last month

HBMHF
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Michael D. Patten as Chief Strategy Officer. Michael will be based in the United States and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.

PR Newswire last month

HBMHF
March 2025's Global Undervalued Small Caps With Insider Buying

As global markets grapple with declining consumer confidence and persistent inflation, small-cap stocks have faced increased volatility, with indices like the Russell 2000 experiencing notable downturns. Despite these challenges, opportunities may arise for discerning investors who focus on companies exhibiting strong fundamentals and strategic insider buying, which can signal potential value amidst broader market uncertainties.

Simply Wall St. last month

HBMHF

SYBJF

ABCGF
HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies

HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders.

PR Newswire last month

HBMHF
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological s

PR Newswire 2 months ago

HBMHF
LifeTech Scientific And 2 More Penny Stocks With Promising Potential

Global markets have been experiencing a mix of highs and uncertainties, with U.S. stock indexes nearing record levels despite inflation concerns that have influenced interest rate expectations. In such a climate, the appeal of penny stocks remains noteworthy as they offer potential opportunities for investors seeking growth in smaller or newer companies. While the term "penny stocks" might seem outdated, their affordability combined with strong financial underpinnings can present promising...

Simply Wall St. 2 months ago

HBMHF

LFTSF
Harbour BioMed Announces Business Progress and Update

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the latest business progress and update.

PR Newswire 2 months ago

HBMHF
February 2025 Undervalued Small Caps With Insider Action Across Regions

In February 2025, the global markets are navigating a complex landscape marked by fluctuating economic indicators and geopolitical tensions. The S&P 600 for small-cap stocks has faced volatility due to AI competition fears and tariff risks, reflecting broader market sentiment that could impact small-cap companies. In this environment, identifying promising small-cap stocks often involves looking at those with strong fundamentals and potential resilience in the face of economic uncertainty.

Simply Wall St. 2 months ago

TFBANK.ST

SYBJF

HBMHF
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM9378/SKB378 (also known as WIN378), a fully human antibody targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic

PR Newswire 2 months ago

HBMHF
Quanzhou Huixin Micro-credit And 2 Other Promising Penny Stocks To Watch

As global markets navigate a landscape marked by inflation concerns and political uncertainties, investors are keeping a close eye on small-cap stocks, which have recently underperformed compared to their larger counterparts. For those interested in exploring smaller or newer companies, penny stocks—an investment area that remains relevant despite the term's vintage feel—can offer intriguing opportunities. By focusing on companies with solid financial foundations and potential for growth,...

Simply Wall St. 3 months ago

1577.HK

HBMHF

1854.HK
Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD

Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical proof of concept of its lead program and IND-enablement of bispecificsLead program is a phase 2-ready, long-acting anti-TSLP monoclonal antibody with potential to be first-to-market with dosing every 6 monthsBuilding a discovery pipeline of long-acting bispecifics harnessing validated targets and syner

GlobeNewswire 3 months ago

HBMHF

6990.HK
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, today announced that the Company and Sichuan Kelun Biotech BioPharmaceutical (HKEX: 06990, "Kelun-Biotech") have entered into a license agreement with Windward Bio AG ("Windward Bio") for HBM9378/SKB378, an anti-thymic stromal lymphopoietin (TSLP) fully human monoclonal antibody co-

PR Newswire 3 months ago

HBMHF
HBM Holdings And 2 Other Promising Penny Stocks

As global markets navigate a complex landscape of interest rate changes and economic data, investors are increasingly looking for opportunities in niche areas like penny stocks. Although the term "penny stocks" may seem outdated, it still refers to smaller or newer companies that can offer significant growth potential when backed by strong financial health. In this article, we will explore three such penny stocks that stand out for their robust balance sheets and potential for long-term success.

Simply Wall St. 4 months ago

HBMHF

D8DU.SI

0621.HK
3 Promising Penny Stocks With Market Caps Over US$70M

As global markets navigate the uncertainties surrounding the incoming Trump administration, investors are keenly observing sector shifts and policy implications. Amid these developments, penny stocks continue to capture attention for their potential to offer value and growth opportunities at accessible price points. Although the term 'penny stocks' may seem outdated, these smaller or newer companies can present significant upside when backed by robust financials. In this article, we explore...

Simply Wall St. 5 months ago

9686.HK

SIMTF

HBMHF
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, is pleased to announce the appointment of Dr. Raymond Zheng as Chief Business Officer (CBO). Based in the United States, Dr. Zheng will lead global business development and alliance management functions, reporting directly to Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.

PR Newswire 5 months ago

HBMHF
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced the submission of an Investigational New Drug (IND) application to the Centre for Drug Evaluation of the National Medical Products Administration of China for HBM9378/SKB378, a fully human antibody targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic

PR Newswire 5 months ago

HBMHF

Performance Overview

Return	6XY.F	HANG SENG INDEX (^HSI)
YTD	+366.32%	+9.58%
1-Year	+741.12%	+27.17%
3-Year	+86.72%	+10.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

HBM Holdings Limited (6XY.F)

Harbour BioMed Appoints Youchen Chen as Chief Financial Officer

Harbour BioMed Reports Full Year 2024 Financial Results

Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies

Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies

Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer

March 2025's Global Undervalued Small Caps With Insider Buying

HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies

Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development

LifeTech Scientific And 2 More Penny Stocks With Promising Potential

Harbour BioMed Announces Business Progress and Update

February 2025 Undervalued Small Caps With Insider Action Across Regions

Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Quanzhou Huixin Micro-credit And 2 Other Promising Penny Stocks To Watch

Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD

Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

HBM Holdings And 2 Other Promising Penny Stocks

3 Promising Penny Stocks With Market Caps Over US$70M

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Performance Overview